Ketamine for Treatment-Resistant Bipolar Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 4, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Bipolar DisorderBipolar DepressionBipolar I DisorderBipolar II Disorder
Interventions
DRUG

Ketamine Hydrochloride

36 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg

DRUG

Midazolam Hydrochloride

36 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg

Trial Locations (3)

M5G 2C4

RECRUITING

Toronto General Hospital, Toronto

M5T 2S8

RECRUITING

Toronto Western Hospital, Toronto

L1N 5S9

ACTIVE_NOT_RECRUITING

Ontario Shores Centre for Mental Health Sciences, Whitby

All Listed Sponsors
lead

Joshua Rosenblat

OTHER